The CASP4 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the CASP4 gene in the human A-549 lung adenocarcinoma epithelial cell line. This pooled knockout model provides a versatile loss-of-function tool for investigating caspase-4-dependent signaling pathways without clonal selection, maintaining the genetic diversity typical of a polyclonal edited population.
The A-549 host cell line was originally derived from lung adenocarcinoma tissue of a 58-year-old male and exhibits an adherent epithelial morphology. Widely used as an in vitro model for lung adenocarcinoma, A-549 cells retain characteristic epithelial features and innate immune responsiveness, making them suitable for studying inflammation-driven processes in a tumor-relevant context.
Caspase-4, encoded by CASP4, functions as an intracellular sensor for lipopolysaccharide (LPS) and serves as the principal initiator of the non-canonical inflammasome pathway. Activated by upstream signals including type I interferons and NF-??B, caspase-4 directly interacts with LPS and mediates cleavage of gasdermin D (GSDMD), leading to pyroptotic cell death. Additionally, caspase-4 promotes maturation and release of the pro-inflammatory cytokines IL-1?? and IL-18, often in cooperation with the adaptor ASC and the NLRP3 inflammasome. This signaling node integrates innate immune detection of cytosolic LPS with downstream inflammatory responses and lytic cell death.
In the A-549 lung adenocarcinoma background, CASP4 knockout enables dissection of non-canonical inflammasome signaling within epithelial tumor cells, offering insights into how loss of caspase-4 affects pyroptosis and the inflammatory microenvironment. Given the emerging link between chronic inflammation and lung adenocarcinoma progression, these cells provide a relevant platform to study CASP4-dependent mechanisms in cancer-associated inflammation, as well as broader roles in sepsis, inflammatory bowel disease, and colorectal cancer.
Research applications include LPS stimulation experiments coupled with Western blotting for cleaved gasdermin D, RT-qPCR analysis of downstream cytokine transcripts, and LDH release assays to quantify pyroptosis. The cells are also suitable for IL-1?? ELISA, caspase-4 cleavage monitoring, and cell viability studies under inflammatory challenge. They support host-pathogen interaction investigations and drug screening for anti-inflammatory compounds targeting the non-canonical inflammasome axis. For additional information or technical inquiries, please contact Ascent Research.
